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Abstract
Introduction: Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin a (LTa), a transiently
expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA)
pathogenesis. This study was conducted to assess the safety, tolerability, < NOTE: For clarity and per AMA/S-W
Style, please restore the use of Oxford/serial commas (ie: David likes vanilla, strawberry, and chocolate ice cream)
throughout. and biologic activity of single and multiple doses of intravenous (IV) or subcutaneous (SC)
pateclizumab in RA patients.
Methods: The single ascending dose (SAD) phase in patients with stable RA consisted of six cohorts (4:1 active:
placebo at 0.3 mg/kg IV, 1.0 mg/kg IV, 1.0 mg/kg SC, 3.0 mg/kg IV, 3.0 mg/kg SC, and 5.0 mg/kg IV; n = 5/cohort).
In the multiple ascending dose (MAD) phase, patients with prespecified RA disease activity received three doses of
pateclizumab or placebo (4:1) every 2 weeks (1.0 mg/kg SC, n = 10; 3.0 mg/kg SC, n = 20; or 5.0 mg/kg IV, n = 5).
Safety and tolerability were assessed throughout, and clinical activity was determined after three doses (Week 6).
Results: We observed no serious adverse events (AEs) or dose-limiting toxicities, and the majority of AEs were mild
to moderate. The pharmacokinetic profiles were linear, and clearance was independent of dose. Reductions in
levels of serum CXCL13 were observed, supporting the biologic activity of pateclizumab on the LTa pathway.
Patients receiving pateclizumab in the 3.0 mg/kg MAD group (3.0 mg/kg SC) demonstrated ACR20, ACR50, and
ACR70 response rates at week 6 of 75%, 56% and 25%, respectively, compared with 57%, 29%, and 0% in the
placebo group. The median Disease Activity Score in 28 joints, C-reactive protein, reduction was 28% for
pateclizumab, versus 8.4% for placebo.
Conclusions: Pateclizumabwas generally well-tolerated in RA patients. Preliminary evidence of clinical activity was
observed in active RA patients at the dose level targeted for clinical effect.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
inflammatory disease associated with progressive joint
damage, pain, fatigue, and disability. Despite advances in
the treatment of RA, a significant proportion of patients
do not achieve an adequate clinical response upon treat-
ment with available therapies, and less than half of
patients who do respond to therapy achieve complete
remission [1]. Current biologic treatment options for the
management of RA often target the proinflammatory
cytokine TNF-a; however, these agents are associated
with safety concerns, such as increased risk of serious
infection [2]. In addition, intolerance to or contraindica-
tion of an existing therapy may further limit a patient’s
therapeutic alternatives.
Depletion of cellular subsets implicated in RA immu-
nopathogenesis has demonstrated significant clinical
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efficacy [3]. Novel therapies that both target the cellular
source of multiple proinflammatory cytokines and inter-
rupt the autoimmune inflammatory cycle perpetuated in
RA could lead to improved outcomes compared to
existing treatments.
Lymphotoxin a (LTa), a member of the TNF super-
family, is both secreted (as the homotrimer LTa3) and
transiently expressed on the cell surface of activated B,
Th1 and Th17 cells, where it forms a complex with LTb
as LTa1b2 heterotrimers [4-6] (Figure 1). Soluble LTa3
binds TNF receptor (TNFR) types I and II, whereas cell-
bound LTa1b2 heterotrimers bind LTb receptors
(LTbR), resulting in the downstream secretion of proin-
flammatory cytokines and chemokines, such as chemo-
kine (C-X-C motif) ligand 13 (CXCL13) [7]. In addition,
signaling through the LTbR pathway is required for the
normal development of secondary lymph nodes and
orchestration of robust germinal center architecture,
and is also implicated in the development of ectopic
lymphoid structures in chronically inflamed tissue [8].
LTa expression is also associated with the pathogen-
esis of RA. Ectopic lymphoid structures are present in
synovial tissue from patients with RA [9], and both tri-
meric forms (LTa3 and LTa1b2) are elevated in the
synovial fluid of patients with RA [10]. Furthermore,
LTa, LTb and LTbR transcripts are elevated in RA
synovium [11-13].
A mouse-specific depleting mAb targeting surface
LTa has been shown to ameliorate inflammation and
arthritis in murine models of disease [6]. In the col-
lagen-induced arthritis (CIA) model, mouse anti-LTa
efficacy has been attributed to depletion of Th1 and
Figure 1 Mechanism of action of MLTA3698A. Lymphotoxin a (LTa) is a cytokine that is transiently expressed (as a secreted homotrimer or
expressed together with LTb on the cell surface) by subsets of activated T cells (Th1, Th17) and activated B cells (B) that are implicated in the
pathogenesis of rheumatoid arthritis autoimmunity. Pateclizumabbinding to LTa expressed on the cell surface results in both the specific
depletion of the activated cells and inhibition of immune cell trafficking and/or recruitment to inflammatory sites while leaving non-LTa-
expressing cells such as Th2 unaffected. TNFR = tumor necrosis factor receptor; LTbR = lymphotoxin b receptor.
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Th17 cells, which are T-cell subsets that express LTa
and are pathogenic drivers of disease. To date there are
no therapies that specifically target these T-cell subsets.
Pateclizumab (MLTA3698A), a humanized mAb, spe-
cifically binds LTa in both the soluble LTa3 homotri-
meric form and the surface-expressed LTa1b2
heterotrimer. Pateclizumab interferes with binding of LT
trimers to its cognate receptors LTbR and TNFR and
has the potential to deplete subsets of LTa-expressing
cells. In this randomized, double-blind, placebo-con-
trolled phase I study of 65 patients with active RA, we
show the safety and activity of pateclizumab.
Materials and methods
We designed this randomized, double-blind, placebo-
controlled trial to evaluate the safety, tolerability, phar-
macokinetics (PK), pharmacodynamics (PD), and preli-
minary evidence of biologic activity of pateclizumab in
patients with RA. Study participants were recruited from
26 centers in the United States and Hungary. The insti-
tutional review boards at each study site approved the
protocol, and all subjects provided their written
informed consent. The trial was registered under US
National Institutes of Health ClinicalTrials.gov identifier
NCT00888745.
Patients
Patients 18 to 75 years of age with a diagnosis of RA
according to the American College of Rheumatology
(ACR) 1987 revised criteria for RA [14] for at least 6
months were eligible for inclusion. Prior to randomiza-
tion, patients must have been maintained on a stable
disease-modifying antirheumatic drug (DMARD) regi-
men. Methotrexate up to 25 mg/week for 4 weeks, leflu-
nomide up to 20 mg/day for 8 weeks, sulfasalazine up
to 3 g/day for 6 weeks, hydroxychloroquine up to 400
mg/day for 8 weeks, or oral prednisone (or its equiva-
lent) up to 10 mg/day at a stable dose for 4 weeks, were
permitted.
Patients enrolled in the single ascending dose (SAD)
stage had RA and were being treated with a stable
DMARD regimen without prespecified disease activity.
Patients enrolled in the multiple ascending dose (MAD)
stage were being treated with a stable DMARD regimen,
had received previous treatment with no more than one
biologic agent and were also required to have moderate
RA disease as defined by a swollen joint count (SJC) ≥ 5
(of 66), a tender joint count (TJC) ≥ 5 (of 68), and C-
reactive protein (CRP) ≥ 1.0 mg/dl.
Study design
In the SAD phase of the study, 30 patients (n = 5/
cohort) were enrolled sequentially into six cohorts of
five patients each (treatment allocation 4:1
pateclizumab:placebo) with four intravenous (IV) dose
levels (0.3, 1.0, 3.0, and 5.0 mg/kg with 1-hour IV infu-
sion; cohorts A, B, D and F, respectively) and two sub-
cutaneous (SC) dose levels (1.0 and 3.0 mg/kg; cohorts
C and E) (Table 1). Patients were enrolled into the next
dose cohort 14 days after administration of the study
drug from the last patient in the previous dose cohort.
All patients in the SAD phase were followed for 12
weeks after the last dose of the study drug, with follow-
up visits at Weeks 2, 4, 6, 8, and 12.
In the MAD phase of the study, 35 patients were
enrolled sequentially into three cohorts with the same
treatment allocation of 4:1 active:placebo (1.0 mg/kg SC,
n = 10; 3.0 mg/kg SC, n = 20; and 5.0 mg/kg 1-hour IV
infusion, n = 5; cohorts G, H, and I, respectively). Prior
to enrollment of the MAD dose cohorts, all available
safety data were reviewed for all patients from the SAD
phase of the study through at least 14 days of follow-up.
Patients in the MAD cohorts received three doses of the
study drug at 2-week intervals (0, 2, and 4 weeks). To
enable detection of early clinical activity, 20 patients
were enrolled in the target dose cohort 3.0 mg/kg SC
(16 patients received active drug and 4 received pla-
cebo). All patients were followed for 12 weeks after the
last dose of the study drug, with follow-up visits at
Weeks 6, 8, 10, 12, and 16.
Assessments
Safety
Safety data were collected at each visit and graded
according to the National Cancer Institute Common
Toxicity Criteria Adverse Event version 3.0 (National
Cancer Institute, Frederick, MD, USA).
Pharmacokinetic assessments
In the SAD phase of the study, PK serum samples were
obtained at predose, 1 hour (IV only) and 4 hours after
dosing on study day 1, then on study Days 2, 4, 8, 15,
Table 1 Study schema for single-dose and multiple-dose
escalation stagesa
Stage dose and route Patients, n (active:placebo)
SAD stage dose, route (cohort)
0.3 IV (A) 4:1
1.0 IV (B) 4:1
1.0 SC (C) 4:1
3.0 IV (D) 4:1
3.0 SC (E) 4:1
5.0 IV (F) 4:1
MAD stage dose, route (cohort)
1.0 SC (G) 8:2
3.0 SC (H) 16:4
5.0 IV (I) 4:1
aIV = intravenously; MAD = multiple ascending doses; SAD = single ascending
dose; SC = subcutaneously.
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22, 29, 43, and 57. In the MAD phase of the study, PK
serum samples were obtained on Day 1 (predose, 1 hour
postdose IV only); Days 4, 8, and 15 (predose, 1 hour
after the end of the IV infusion only); Days 18 and 29
(predose 1 and 4 hours after the end of the IV infusion
only); and Days 30, 32, 36, 43, 57, 71, and 85. PK sam-
ples were analyzed using a validated ELISA with a lower
limit of quantification of 100 ng/ml.
For anti-therapeutic antibody measurement, serum
samples were collected at Day 1 (predose), 29 (predose),
and 57 in the SAD stage. For the MAD stage, samples
were collected at Day 1 (predose), 29 (predose), 57, and
85. On the basis of the assay validation data, the mea-
sured anti-pateclizumab responses are not likely to be
enhanced by soluble LTa cross-reactivity, and the assay
is formatted appropriately to reduce drug interference
(data not shown).
Pharmacodynamic biomarker assessments
In the SAD phase of the study, PD serum samples were
obtained at screening, Day 1 (predose) and Days 2, 4, 8,
15, 22, 29, 43, and 57. In the MAD phase of the study,
serum samples were obtained at screening, Day 1 (pre-
dose) and Days 8, 15, 29, 36, 43, 57, 71, and 85. In all
cohorts, levels of CXCL13 and total soluble LTa (free
and drug bound LTa, which may include all trimeric
forms) were assessed by ELISA with lower limits of
quantification of 15.6 pg/ml and 100 pg/ml, respectively.
Clinical activity assessments
Exploratory analyses were conducted for the MAD stage
to evaluate the effect of pateclizumab on the clinical
response variables, including ACR20 and ACR50 (20%
and 50% improvement, respectively, in tender or SJCs,
as well as 20% and 50% improvement, respectively, in
three of the other five American College of Rheumatol-
ogy criteria for RA), Disease Activity Score in 28 joints
(DAS28) responses and C-reactive protein (CRP) These
analyses were performed at week 6, two weeks after the
last dose of study drug.
Statistical analysis
All patients who received at least one dose of the study
drug were included in the safety, PK, and PD analyses.
Adverse events (AEs), vital signs, laboratory tests, PK,
and evidence of biologic activity were descriptively com-
pared across the various treatment groups with no for-
mal statistical testing.
For disease activity measurements, data were censored
for patients who received a new or increased dose of a
DMARD or who withdrew from the study. For all
patients who received pateclizumab, censored data were
imputed as the highest disease activity score in the cor-
responding cohort at the corresponding time point for
active patients (or lowest activity for that patient, which-
ever was lower). For patients who received placebo,
censored data were imputed as the last observation
recorded for that patient.
PK was assessed by noncompartmental analysis using
WinNonlin Professional version 5.2.1 software (Phar-
sight, Mountain View, CA, USA). Preliminary popula-
tion PK modeling was conducted to estimate the
bioavailability following SC dosing using all the available
SAD and MAD PK data (NONMEM 7.2, ICON Devel-
opment Solutions, Ellicott City, MD, USA).
Results
Study population
Of the 65 patients enrolled in the study, 45 patients
were from the United States and 20 patients were from
Hungary. Patient demographics were balanced between
active drug and placebo recipients (Table 2) in both the
SAD and the MAD stages of the study. As anticipated
based on the inclusion criteria, patients in the MAD
phase of the study had greater baseline disease activity
than patients in the SAD phase. At baseline, patients in
the MAD phase of the study had had a diagnosis of RA
for a median of 8 years (IQR = 4 to 11, range = 0.6 to
30), with a median baseline CRP of 1.7 mg/dL (IQR =
1.3 to 3, range = 0.9 to 4.6), median erythrocyte sedi-
mentation rate of 31 mm/hr (IQR = 24 to 64, range =
11 to 97), median SJC of 9 (IQR = 9 to 16, range = 5 to
45), median TJC of 17 (IQR = 11 to 31, range = 5 to
65) and a median DAS28-CRP score of 5.6 (IQR = 4.9
to 5.9, range = 3.9 to 7.9). In addition, in the MAD
phase of the study, patients who received pateclizumab
had higher baseline disease activity based on SJCs and
TJCs, as well as higher CRP measurements.
Patient disposition
Overall, 97% of patients in the pateclizumab-treated
groups and 100% of patients in the placebo groups com-
pleted the study. One patient in cohort G (MAD 1 mg/
kg SC) who received active drug discontinued the study
at day 20 because of an RA flare after having received
two doses of the study drug. Clinical activity data were
censored for an additional seven patients in the MAD
phase of the study (6 of 28 receiving pateclizumab and 1
of 7 receiving placebo) who received adjunctive steroid
therapy during the course of the study.
Safety
Pateclizumabwas well-tolerated during the study. There
were no serious AEs and no dose-limiting toxicities. No
AEs resulted in the withdrawal of the study drug.
Twenty patients in the SAD phase reported a total of 44
AEs. The overall incidence of AEs was slightly higher in
pateclizumab-treated patients than in placebo-treated
patients (71% and 50%, respectively) (Table 3). Twenty
patients in the MAD phase reported a total of 54 AEs,
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with both treatment groups experiencing comparable
rates of AEs (57% in pateclizumab-treated patients and
57% in placebo-treated patients). Nearly all (97%) of the
AEs were grade 1 or 2. All three grade 3 AEs in patients
receiving pateclizumabwere reported as unrelated to
study drug administration.
There was no trend toward an increased incidence of
AEs with increasing doses of pateclizumab. The most
























Sex, female:male 6:0 20:4 7:0 6:2 14:2 3:1 23:5














Race, white:black 5:1 23:1 7:0 7:1 16:0 3:1 26:2
Region, USA:Hungary All USA All USA 3:4 6:2 5:11 2:2 13:15
Disease characteristics
Median disease duration, years 3 5 5.4 9 7.5 7 8
RF- and anti-CCP-positive (%) 17 67 71.4 87.5 87.5 50.0 82.1
Concomitant medications (%)
Prior anti-TNF-a 33 33 0 25 19 0 18
MTX 67 63 29 13 44 50 36
Leflunomide 0 4 43 38 6 25 18
Steroids 33 25 57 50 69 75 54










































































aCCP = cyclic citrullinated peptide; CRP = C-reactive protein; DAS28-CRP = Disease Activity Score in 28 joints, C-reactive protein; ESR = erythrocyte sedimentation
rate; IV = intravenously; MAD = multiple ascending dose; MTX = methotrexate; RA = rheumatoid arthritis; RF = rheumatoid factor; SAD = single ascending dose;
SC = subcutaneously; SJC = swollen joint count; TJC = tender joint count.
Table 3 Treatment-emergent adverse events by preferred term occurring in at least two patients from all
pateclizumab-treated groups combined during either single or multiple ascending dose phasesa















Any event 3 (50.0) 20 (66.7) 4 (57.1) 7 (87.5) 8 (50.0) 1 (25.0) 20 (57.1)
Fatigue 0 (0.0) 2 (8.3) 1 (14.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Rheumatoid arthritis 0 (0.0) 2 (8.3) 0 (0.0) 1 (12.5) 1 (6.3) 0 (0.0) 2 (7.1)
Rash 0 (0.0) 2 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Diarrhea 0 (0.0) 1 (4.2) 0 (0.0) 3 (37.5) 1 (6.3) 0 (0.0) 4 (14.3)
Vomiting 0 (0.0) 0 (0.0) 0 (0.0) 2 (25.0) 0 (0.0) 0 (0.0) 2 (7.1)
Nasopharyngitis 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (12.5) 0 (0.0) 2 (7.1)
Headache 0 (0.0) 1 (4.2) 0 (0.0) 2 (25.0) 1 (6.3) 1 (25.0) 4 (14.3)
Rhinorrhea 0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 1 (6.3) 0 (0.0) 2 (7.1)
aIV = intravenously; MAD = multiple ascending dose; SAD = single ascending dose; SC = subcutaneously.
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common AEs reported in the active arm were musculos-
keletal, gastrointestinal, and headache. There was a sin-
gle injection site reaction in a patient who experienced
injection site pain in the 3.0 mg/kg SC cohort in the SD
stage of the study. There were no increased rates of
infections in patients receiving pateclizumabcompared
to placebo. In addition, there were no significant differ-
ences over time in total lymphocytes, T cells, or B cells
between patients receiving pateclizumabcompared to
placebo (data not shown).
Immunogenicity
Of the 52 patients treated with pateclizumab, anti-pate-
clizumabantibodies were detected in a total of seven
patients. In the IV cohorts, 1 of 20 patients was anti-
pateclizumabantibody-positive. In the SC groups, 6 of
32 patients were anti-pateclizumabantibody-positive.
There were no anti-pateclizumabantibodies detected in
placebo-treated patients or at any predose time points.
Efficacy outcomes
Clinical activity was assessed at Week 6, 2 weeks after
the last dose of the study drug. Cohort H was used for
evaluation of biologic activity based on the dose (3.0
mg/kg SC) and expanded sample size (n = 20). Baseline
disease activity scores, as measured by DAS28-CRP and
CRP, were comparable between those patients receiving
pateclizumabin cohort H and patients receiving placebo
(pooled placebo data across all MAD cohorts).
A total of 75%, 56%, and 25% of patients treated with
3 mg/kg pateclizumabSC achieved an ACR20, ACR50,
and ACR70 responses, respectively (Figure 2A). In com-
parison, 57%, 29%, and 0% of the patients receiving pla-
cebo achieved ACR20, ACR50, and ACR70 scores.
Patients receiving pateclizumaband placebo had median
baseline DAS28-CRP scores of 5.44 and 5.69. At week 6,
patients receiving pateclizumabhad a median DAS28-
CRP score of 3.47 with a median reduction of 1.22. Pla-
cebo patients’ median score was 4.86, with a median
reduction of 0.82 (Figure 2B). At Week 6, median CRP
measurements had decreased 28% from baseline in pate-
clizumab-treated patients compared to 8% among pla-
cebo-treated patients (Figure 2C). Patients receiving
multiple doses pateclizumabat 3.0 mg/kg SC indicated
preliminary evidence of clinical activity on all three pre-
specified end points. When patients were followed to
Week 10 (6 weeks after the last dose of the study drug),
ACR50 responses were sustained, with 50% of patients
receiving pateclizumabmaintaining an ACR50 response
compared with 14% of placebo-treated patients (Figure
2D).
Patients receiving pateclizumabin a lower-dose MAD
cohort (cohort G, 1.0 mg/kg SC; n = 10) did not show
evidence of clinical activity. Data from two patients were
imputed (one patient received prednisone on day 2 of
the study and another withdrew after two doses because
of RA flare). Thus, at the 6-week end point, our sample
size was too limited for characterization of efficacy. In
the highest-dose cohort (cohort I, 5.0 mg/kg IV), the
presence of clinical activity was observed in a single
patient (one of four receiving pateclizumab) with an
ACR70 score; however, the interpretation of a dose
response is limited because of the small number of
patients in this cohort.
In the expanded cohort (3.0 mg/kg SC), 7 of 16
patients were taking methotrexate and 3 of 16 patients
had previously received TNF blockade. There was no
clear difference in efficacy based on the use of metho-
trexate. Four of seven patients taking methotrexate
achieved a score of ACR50, whereas three of nine
patients not receiving methotrexate achieved an ACR50
score. The median reductions from baseline in DAS28-
CRP scores were 1.37 and 1.07 (mean reductions in
DAS28-CRP of 0.84 and 1.04,) in those who were and
were not receiving methotrexate. Of the three patients
who had previously received TNF blockade, none
achieved an ACR50 score. Four patients in the 3.0 mg/
kg SC expanded cohort developed anti-pateclizumaban-
tibodies. Three of these patients also achieved an
ACR50 score, despite the development of anti-
pateclizumabantibodies.
Pharmacokinetics
Pateclizumabconcentration and time profiles displayed
biexponential decay after IV administration (Figure 3A).
Overall, pateclizumabexposure, as measured by maxi-
mum serum concentration (Cmax) and area under the
concentration time curve (AUC), were approximately
dose-proportional after single or multiple doses. After a
single dose, the cohort mean clearance (CL) and term-
inal half-life (t1/2) ranged from 4.54 to 7.03 ml/day/kg,
and 8 to 15 days, respectively. The bioavailability follow-
ing SC dosing was approximately 43%. After three doses
of pateclizumabat 1 or 3 mg/kg SC, or 5 mg/kg IV at 2-
week intervals (0, 2, and 4 weeks), the mean accumula-
tion index ranged from 1.77 to 1.88. The mean CL and
t1/2 values from the MAD cohorts were similar to those
from the SAD cohorts.
Pharmacodynamics
Decreases in CXCL13 after administration of pateclizu-
mabwere observed in the SAD and MAD phases in all
cohorts receiving doses ≥ 1 mg/kg pateclizumab (Figure
3B). Decreases in CXCL13 levels following pateclizuma-
badministration indicated biological activity. Increases in
soluble LTa were observed in all cohorts given anti-
LTa, with minimal elevation at the lowest doses (0.3
mg/kg IV and 1 mg/kg SC) and no changes in the
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placebo group. Maximal increases occurred at 3 mg/kg
SC. These results are consistent with the expected for-
mation of pateclizumab-LTa complexes and an
increased half-life of soluble LTa upon binding to pate-
clizumab. Similar results were observed in preclinical
studies in cynomolgus monkeys [15].
Correlative analysis of pharmacodynamics and
pharmacokinetics
Maximum decreases in CXCL13 (PD effects) were con-
sistently observed at serum drug concentrations of ≥ 1
to 10 μg/ml across all anti-LTa cohorts with ≥ 1 mg/kg
doses (Additional file 1). There was no apparent correla-
tion between decreases in CXCL13 and pateclizumabC-
max, or AUC.
Discussion
In this phase I study, pateclizumab, a humanized mAb
that specifically binds LTa, was well-tolerated in
patients with active RA. Using an expanded cohort
approach, preliminary evidence of clinical activity was
observed at the prespecified target dose of 3 mg/kg SC
as measured by reduction in DAS28-CRP scores,
reduction of CRP values, and achievement of ACR20,
ACR50, and ACR70 responses. PK data revealed linear
biphasic kinetics with dose proportionality. CXCL13
reduction as a PD marker was observed, supporting the
anticipated effect of pateclizumabon downstream signal-
ing via the LTa pathway.
Pateclizumabis a humanized mAb against the cytokine
LTa. It is thought to act both by selectively depleting a
specific subset of LTa-expressing activated T and B
cells and by blocking LTa-mediated signaling (Figure 1).
LTa is expressed on subsets of Th1 and Th17 T cells,
as well as on activated B cells, but is absent from other
subsets, such as Th2 [6]. Pateclizumablikely exerts its
effects farther upstream than TNF inhibitors by target-
ing the cellular source of multiple proinflammatory
cytokines. In a preclinical model of CIA, a murine anti-
body targeting LTa showed clinical efficacy by specifi-
cally depleting LTa-expressing lymphocytes, resulting in
decreased joint pathology and rapid reduction of TNF-
a, IL-1b and IL-6 levels within the hindpaw [6]. Impor-
tantly, the murine antibody had no effect in a Th2-dri-
ven model of asthma, demonstrating selectivity of anti-
LTa for Th1 and Th17 cells.
Placebo


















































































































Figure 2 Clinical activity in patients receiving 3 mg/kg SC pateclizumabor placebo. ACR20, ACR50 and ACR70 = 20%, 50% and 70%
improvement, respectively, in tender or swollen joint counts, as well as 20%, 50% and 70% improvement, respectively, in three of the other five
American College of Rheumatology criteria for rheumatoid arthritis; DAS28-CRP = Disease Activity Score in 28 joints, C-reactive protein; SC =
subcutaneously.
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This phase I study of patients with moderate to severe
RA was designed to assess the safety and tolerability of
pateclizumaband to evaluate preliminary evidence of
clinical activity. pateclizumabwas well-tolerated in
patients receiving IV or SC administration of either sin-
gle or multiple doses. The majority of AEs were grade 1
or 2, with no serious AEs and no withdrawal of the
study drug due to AEs. Importantly, no serious infec-
tions were reported during the study, and no increased
rate of infections was reported in patients receiving
pateclizumabcompared with placebo. PK analysis
revealed that exposure to pateclizumabwas approxi-
mately dose-proportional. Anti-pateclizumabantibodies
were detected in 7 of 52 pateclizumab-treated patients,
but without any clinical sequelae.
CXCL13 is a chemokine induced downstream of LTbR
signaling which has been implicated in the formation of
ectopic lymphoid structures [11,12,16]. Elevated
CXCL13 serum levels have been associated with synovi-
tis in RA [17], and serum CXCL13 is decreased follow-
ing treatment of RA patients with TNF-a inhibitors and
anti-CD20 rituximab [17-19], thus implicating CXCL13
as a robust biomarker of RA disease activity. In our PD
evaluations, pateclizumabadministration maximally
decreased CXCL13 levels in all dose cohorts ≥ 1.0 mg/
kg SC or IV. The reduction in CXCL13 most likely
reflects an effect on downstream events following inter-
ruption of the LTa pathway.
The 3.0 mg/kg SC cohort in the MAD phase of the
study consisted of an expanded cohort designed to
Figure 3 Mean (± SD) serum pateclizumabpharmacokinetic profiles (A) and CXCL13 profiles (B) by cohort. CXCL13 is presented as the
percentage change from baseline. Arrows indicate pateclizumabdoses. BL = baseline; CXCL13 = chemokine (C-X-C motif) ligand 13; IV =
intravenously; LTa = lymphotoxin a; MAD = multiple ascending dose; SAD = single ascending dose; SC = subcutaneously.
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evaluate clinical activity of pateclizumabat the target
dose. Clinical response variables were assessed at week 6
(2 weeks after the last dose of drug). ACR20, ACR50,
and ACR70 response rates were seen in 75%, 55%, and
25% of patients. In addition to ACR20, ACR50, and
ACR70 responses achieved in this patient cohort, these
patients showed substantial decreases in DAS28-CRP
scores and CRP levels compared to placebo-treated sub-
jects. Overall, for all measures evaluated, there was pre-
liminary evidence of clinical activity in patients receiving
pateclizumabcompared to placebo. Furthermore, evi-
dence of sustained clinical activity was observed, with
50% of patients maintaining an ACR50 score up to 6
weeks after receiving their last dose of the study drug.
The concomitant use of methotrexate did not affect
clinical activity results. None of the three patients who
had previously received TNF blockade achieved an
ACR50 score. However, the small number of these
patients limits the interpretation of activity in these sub-
populations of patients who may be receiving (or may
have received) other medications targeting RA disease.
The limitations of this study include the small sample
size, which restricts interpretation of the study results.
Regarding clinical activity, the other MAD dose cohorts
(1.0 mg/kg SC and 5.0 mg/kg IV) were not designed as
expanded cohorts, thus the ability to detect a dose
response was limited by the small number of patients
within these cohorts. In addition, patients were recruited
from only two countries for this study (the United States
and Hungary). Larger global studies will allow the eva-
luation of the effect of pateclizumabacross a broader RA
patient population. Baminercept (a human LTbR-human
immunoglobulin G1 (IgG1) fusion protein) failed to
show clinical benefit in a phase II trial in patients with
RA [20,21]. Although both pateclizumaband baminer-
cept block LTab-induced signaling (via the LTb recep-
tor) [7], it is important to note that pateclizumabis
distinct in its potential to selectively deplete LTa-
expressing cells. In a preclinical murine model of estab-
lished arthritis, a depleting murine anti-LTa antibody
had efficacy comparable to that of anti-TNF-a antibo-
dies, whereas an LTbR/Ig blocker had no effect [6]. In
addition, this murine antibody demonstrated efficacy in
mice that were refractory to anti-TNF administration
[22]. Together these data suggest that the depleting
anti-LTa mAb pateclizumabhas great potential for clini-
cal activity in RA.
Conclusions
Inhibition of the LTa pathway provides a unique
approach by which to abrogate proinflammatory
responses in RA pathology. By blocking signaling
through the LTa pathway, as well as by depleting LTa-
expressing cells, which are dominant sources of TNF-a
and IL-6, pateclizumabis likely to work upstream of
TNF-a blockade. This mechanism may provide an
attractive alternative therapeutic approach for patients
with moderate to severe RA. In this phase I study, pate-
clizumabwas well-tolerated and provided a linear PK
profile when delivered subcutaneously. Given prelimin-
ary evidence of biologic and clinical activity, further eva-
luation of its clinical efficacy is warranted in larger
clinical trials. To further characterize the safety, PK, PD
and clinical activity of pateclizumab, a phase II study of
RA patients without an adequate response to DMARDs
is in progress.
Additional material
Additional file 1: Maximum decreases in CXCL13 (pharmacodynamic
effects) were consistently observed at serum
pateclizumabconcentrations > 1 to 10 μg/ml across all cohorts. The
pateclizumab (circles) and CXCL13 (triangles) concentrations are
presented as means ± SD.
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